BioTime Inc. (BTX)

0.92
AMEX : Health Technology
Prev Close 0.99
Day Low/High 0.90 / 0.97
52 Wk Low/High 0.66 / 2.61
Avg Volume 459.10K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 148.15M
EPS -0.40
P/E Ratio 4.60
Div & Yield N.A. (N.A)
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office Of The Chief Scientist

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office Of The Chief Scientist

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

BioTime Reports Isolation Of Novel Brain-Associated Cells From Human Embryonic Stem Cells

BioTime Reports Isolation Of Novel Brain-Associated Cells From Human Embryonic Stem Cells

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful ...

LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards® Version 3.11

LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards® Version 3.11

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc.

BioTime’s CEO, Dr. Michael West To Moderate Session On Mapping The Cellular Basis Of Life At The 2013 World Stem Cell Summit

BioTime’s CEO, Dr. Michael West To Moderate Session On Mapping The Cellular Basis Of Life At The 2013 World Stem Cell Summit

BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime’s CEO, Dr.

Asterias Biotherapeutics, Inc. Files Registration Statement For Underwritten Public Offering

Asterias Biotherapeutics, Inc. Files Registration Statement For Underwritten Public Offering

Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime CEO Dr. Michael West To Present At 11th Annual Commercial Translation Of Regenerative Medicine Conference

BioTime CEO Dr. Michael West To Present At 11th Annual Commercial Translation Of Regenerative Medicine Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Announces Third Quarter 2013 Financial Results And Recent Corporate Accomplishments

BioTime Announces Third Quarter 2013 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter ended September 30, 2013 and ...

Asterias Biotherapeutics, Inc. Plans To File Registration Statement For Underwritten Public Offering

Asterias Biotherapeutics, Inc. Plans To File Registration Statement For Underwritten Public Offering

Asterias Biotherapeutics, Inc., a majority-owned subsidiary of BioTime, Inc.

BioTime Reports Interim Results On Renevia™ Clinical Safety Trial

BioTime Reports Interim Results On Renevia™ Clinical Safety Trial

BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.

BioTime Organizes New ESI BIO Division To Develop, Manufacture And Market The Company’s Cell-Based Research Products

BioTime Organizes New ESI BIO Division To Develop, Manufacture And Market The Company’s Cell-Based Research Products

BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business.

BioTime, Inc. To Provide Company Updates During Investor Day, October 28, 2013

BioTime, Inc. To Provide Company Updates During Investor Day, October 28, 2013

BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City.

BioTime’s Subsidiary OncoCyte Corporation And The Wistar Institute To Collaboratively Develop Cancer Diagnostics

BioTime’s Subsidiary OncoCyte Corporation And The Wistar Institute To Collaboratively Develop Cancer Diagnostics

BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to ...

BioTime Announces Additional Products In Development Based On HyStem® Technology

BioTime Announces Additional Products In Development Based On HyStem® Technology

BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem ® hydrogel technology platform.

Asterias Biotherapeutics, Inc., A Subsidiary Of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets

Asterias Biotherapeutics, Inc., A Subsidiary Of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets

Asterias Biotherapeutics, Inc. and BioTime, Inc.

BioTime Signs Exclusive Agreement With Jade Therapeutics For Ophthalmic Drug Delivery Applications Of HyStem® Technology

BioTime Signs Exclusive Agreement With Jade Therapeutics For Ophthalmic Drug Delivery Applications Of HyStem® Technology

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with Jade Therapeutics, ...

BioTime Receives Approval To Begin Human Clinical Trials Of Renevia

BioTime Receives Approval To Begin Human Clinical Trials Of Renevia

BioTime, Inc. (NYSE MKT: BTX) today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia™, a unique biomaterial used...

BioTime Announces The Appointment Of Lesley Stolz As Executive Vice President Of Corporate Development

BioTime Announces The Appointment Of Lesley Stolz As Executive Vice President Of Corporate Development

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the expansion of its senior management team with the appointment of ...

BioTime CEO Dr. Michael West To Give Keynote Address At The MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine Conference

BioTime CEO Dr. Michael West To Give Keynote Address At The MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D.

BioTime Announces Second Quarter 2013 Financial Results And Recent Corporate Accomplishments

BioTime Announces Second Quarter 2013 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2013 and ...

BioTime’s Subsidiary OncoCyte Corporation Publishes Data On The Gene FSIP1 As A Breast Cancer-Specific Marker

BioTime’s Subsidiary OncoCyte Corporation Publishes Data On The Gene FSIP1 As A Breast Cancer-Specific Marker

BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene FSIP1 and its potential as a marker for breast cancer.

BioTime Subsidiary LifeMap Sciences Announces Publication Of Research Report Describing LifeMap Discovery™

BioTime Subsidiary LifeMap Sciences Announces Publication Of Research Report Describing LifeMap Discovery™

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc.

BioTime CEO Dr. Michael West To Present At The Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course

BioTime CEO Dr. Michael West To Present At The Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D.

July Options Now Available For BioTime (BTX)

July Options Now Available For BioTime (BTX)

Investors in BioTime, Inc. saw new options begin trading today, for the July expiration.

BioTime Announces Fourth Quarter And Fiscal Year End 2012 Financial Results And Recent Corporate Accomplishments

BioTime Announces Fourth Quarter And Fiscal Year End 2012 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2012 and highlighted its fourth quarter and recent corporate accomplishments.

BioTime To Present At 25th Annual ROTH Conference

BioTime To Present At 25th Annual ROTH Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Dr.

BioTime Appoints Stephen C. Farrell To Board Of Directors

BioTime Appoints Stephen C. Farrell To Board Of Directors

BioTime, Inc. (NYSE MKT: BTX) today announced that Stephen C.

BioTime And Romulus Agree To Accelerate Closing Date For Second Tranche Of $5 Million Financing

BioTime And Romulus Agree To Accelerate Closing Date For Second Tranche Of $5 Million Financing

BioTime, Inc. (NYSE MKT: BTX) today announced it has amended its $5 million Stock and Warrant Purchase Agreement with Romulus Films, Ltd.

(Video: Business Wire)

(Video: Business Wire)

BioTime, Inc. (NYSE MKT: BTX) and its bioinformatics subsidiary LifeMap Sciences, Inc.

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.